Optimizing Antihypertensive Therapy in Chronic Kidney Disease

1. Renin‑Angiotensin System (RAS) Inhibition

• KDIGO strongly recommends (Grade 1B) initiating an ACE inhibitor or ARB in adults with CKD and moderate‑to‑severe albuminuria (A2‑A3), irrespective of diabetes status. 1
• Even when albuminuria data are unavailable, it is considered reasonable to start RAS inhibition in hypertensive CKD patients. 2
• RAS inhibitors should be titrated to the highest approved dose that the patient tolerates, because trial benefits were demonstrated at maximal dosing. (Grade 1B) 3
• After starting an ACEi/ARB, serum creatinine and potassium should be re‑checked 2–4 weeks later; therapy is continued unless creatinine rises > 30 % within 4 weeks. (Grade 1B) 2
• Combining an ACEi, an ARB, and a direct renin inhibitor is contraindicated in CKD. (Grade 1B) 3

2. SGLT2‑Inhibitor Therapy

• KDIGO recommends (Grade 1A) adding an SGLT2 inhibitor to all adults with CKD who have eGFR ≥ 20 mL/min/1.73 m² and albuminuria ≥ 200 mg/g, or who have heart failure. 1
• For patients with eGFR 20–45 mL/min/1.73 m² and albuminuria < 200 mg/g, SGLT2‑inhibitor use is suggested (Grade 2B). 1
• SGLT2 inhibitors confer mortality and kidney‑function benefits that are independent of their modest blood‑pressure‑lowering effect. (Grade 1A) 4
• Once initiated, the SGLT2 inhibitor should be continued even if eGFR falls below 20 mL/min/1.73 m², provided the drug remains tolerated. (Grade 1A) 1
• Temporarily withhold SGLT2 inhibitors during prolonged fasting, major surgery, or critical illness because of the risk of ketosis. (Grade 1B) 1

3. Blood‑Pressure Targets

• Aim for a standardized office systolic blood pressure < 120 mmHg in CKD patients when tolerated. (Grade 1B) 5
• Achieving this intensive target reduces cardiovascular events in CKD. (Grade 1B) 5
• Avoid the <120 mmHg target in individuals who are frail, have a high fall risk, limited life expectancy, or symptomatic orthostatic hypotension. (Grade 2B) 4

4. Medication Optimization Algorithm

5. Monitoring & Safety

• Monitor serum potassium closely; hyperkalemia can often be managed with potassium binders without discontinuing RAS inhibition. (Grade 1B) 2
• Continue ACEi/ARB therapy even when eGFR declines below 30 mL/min/1.73 m², as renal protection persists. (Grade 1B) 4

All facts are derived from KDIGO guidelines and associated peer‑reviewed evidence, with strength of recommendation indicated where provided.

Combining Dapagliflozin with Loop Diuretics: Evidence‑Based Recommendations

Blood‑Pressure Targets in Chronic Kidney Disease

• The American College of Cardiology/American Heart Association recommends a systolic blood‑pressure target < 130 mm Hg (ideally < 120 mm Hg if tolerated) for patients with chronic kidney disease. 6
• Intensive blood‑pressure control (systolic < 120 mm Hg) in CKD patients has been shown to reduce cardiovascular events and all‑cause mortality without worsening the primary kidney outcome. 6
• Uncontrolled hypertension in CKD markedly increases cardiovascular morbidity and mortality, supporting the need for aggressive treatment. 6

Monitoring Renal Function When Adding a Loop Diuretic

• A rise in serum creatinine of ≤30 % after initiating a loop diuretic is considered a hemodynamically mediated, acceptable change; larger increases should prompt evaluation for true volume depletion, nephrotoxins, or renovascular disease. 6
• Small creatinine elevations (<30 %) observed after diuretic initiation are expected hemodynamic shifts and should not be automatically labeled as acute kidney injury. 6

Practical Therapeutic Recommendation

• Adding a low‑dose loop diuretic to a regimen that includes dapagliflozin is advised to achieve blood‑pressure control and enhance potassium excretion, while dapagliflozin should be continued for its proven renal and cardiovascular benefits. Patients should be assessed for volume status before initiation and monitored closely for the first 1–2 weeks. 6

Serum Potassium Monitoring and Management with Lisinopril in Chronic Kidney Disease

Monitoring Frequency

• Serum potassium should be re‑checked 2–4 weeks after any lisinopril dose adjustment and, if stable, subsequently every 4 months【7】.

Management of Mild‑to‑Moderate Hyperkalaemia

• When potassium rises to 5.0–5.5 mmol/L, clinicians should first employ dietary potassium restriction or prescribe potassium‑binding agents rather than stopping the ACE inhibitor【7】.

Criteria for Discontinuation and Re‑initiation

• Lisinopril should be discontinued only if potassium exceeds 5.5 mmol/L despite the above interventions; the drug may be restarted once potassium is reduced to ≤5.0 mmol/L【7】.

Beta‑Blocker Use in Chronic Kidney Disease with Cardiac Indications

Indications and Clinical Benefits

• Beta‑blockers are well tolerated in CKD, do not worsen renal function, and should be prescribed when specific cardiac indications exist—heart failure with reduced ejection fraction, post‑myocardial infarction, or atrial fibrillation—while they are not first‑line agents for uncomplicated hypertension in CKD. 8
• In CKD patients with hypertensive‑related heart failure, beta‑blockers provide strong cardioprotective effects and should be used liberally. 8

Renal Safety Profile

• Beta‑blockers improve renal tissue oxygenation in hypertensive patients with renal artery stenosis, indicating a favorable renal safety profile. 8

Drug Interactions and Combination Therapy

• Beta‑blockers may be combined with any other antihypertensive drugs; however, concurrent use of non‑dihydropyridine calcium‑channel blockers (diltiazem, verapamil) should be avoided in patients with heart failure because of additive negative chronotropic and inotropic effects. 8
• For rapid rate control of atrial fibrillation in CKD, a combination of a beta‑blocker and a non‑dihydropyridine calcium‑channel blocker is considered effective. 8

Practical Recommendations

• Clinicians should not withhold beta‑blockers from CKD patients who have clear cardiac indications (heart failure, post‑MI, atrial fibrillation) based on unfounded concerns about renal toxicity. 8